Europe/Asia USA
Bachem AG Bachem Americas, Inc.
Hauptstrasse 144 3132 Kashiwa Street
4416 Bubendorf - Switzerland Torrance, CA 90505 - USA
Tel +41 61 935 2323 Tel +1 888 422 2436
Fax +41 61 935 2325 +1 888 4BACHEM
E-mail +1 310 539 4171
  Fax +1 310 539 9428


Financial Performance

Fiscal year 2016:
Another year of strong sales and profit growth

  • Momentum intact and new sales record set
  • EBIT margin climbs to 19.1%, EBITDA margin to 27.4%
  • Significantly faster net income growth of 29.4% to 41.2 million CHF
  • Expansion of production capacity, new building for R&D at company headquarters
  • Workforce grows, now numbers more than 1’000
  • Increase in dividend from 2.25 to 2.50 CHF proposed
  • Excellent order situation and better capacity utilization



Bubendorf/Basel, Friday, March 17, 2017 – Bachem Group (SIX: BANB), the market leader in the field of peptide chemistry with a distinctive focus on quality and innovation, set another sales record in the 2016 fiscal year and reported sharply higher earnings. Bachem managed to sustain its very good momentum from the first half of the year throughout the second half. The Group generated full-year sales of 236.5 million CHF (2015: 208.6 million CHF, +13.4% in CHF). Bachem increased its operating profit (EBIT) by 17.0% to 45.1 million CHF. One-off costs associated with legal counsel and the introduction of a new Group-wide Enterprise Resource Planning (ERP) system are included in this figure. Furthermore, the expansion of capacity at American Peptide Company (APC) after its acquisition in 2015 resulted in a brief, scheduled stoppage in production that curtailed the utilization of the Vista, California plant. Despite these extraordinary effects, Bachem widened its EBIT margin to 19.1% (previous year: 18.5%). The EBITDA margin stood at 27.4% (previous year: 27.2%). Net income rose at a proportionately faster pace of 29.4% with some tailwind from positive foreign exchange effects and amounted to 41.2 million CHF (previous year: 31.8 million CHF).



  .... Read the full press release